The Fisher Scientific channel is proud to have been re-awarded as a Preferred Supplier to its members. Under this renewed and expanded agreement, One Nucleus Gold members can benefit from significant cost savings through the established purchasing framework.
In the first four months of 2025 alone, Fisher Scientific delivered £1.97 million in product savings for Gold members from list pricing, including overall price reductions based on the 2024 hotlist pricing.
New for 2025: Enhanced Support for Sustainable Purchasing
The new 2025 Preferred Supplier agreement goes even further—now offering…
by Tony Jones, CEO, One Nucleus
One Nucleus has been busy developing plans for being in Boston from 15 June 2025, complementing the UK@BIO plans where possible, whilst giving members a chance to maximise their return on investment summarised as follows (see also the BIO page on our website). Sunday 15 June 13.00-17.00 Landing Your Company In The Boston Life Science Ecosystem hosted by Life Science Nation
Life Science Nation (LSN) is offering an exclusive opportunity for RESI Boston June 2025 attendees and other international companies in Boston that week to gain invaluable insights…
by Tony Jones, CEO, One Nucleus
Continuing the series of blogs about the way in which One Nucleus views the nurturing of our community to facilitate the success of our members, the focus this time is on how we can leverage technology to enhance the ‘One Nucleus Bump’ effect.
The Value of Human Collisions
In the first two parts of the series, Nurturing Your Local Ambassadors to Enable Your International Success and Creating the Home of Champions, readers may recall how the themes of your network contacts helping to amplify your visibility and why being part of a trusted community leads to…
by Alicia Gailliez, Business Development Manager, One Nucleus
At the end of April, a cohort of early-stage life science companies - Metrion Biosciences, PharmEnable Therapeutics, RNAvate and Tailor Bio - embarked on an intensive programme alongside One Nucleus and supporting sponsors, as well as Cellestial Health and OutSee, on a self-funded basis to join us. Having been selected as the winners of the One Nucleus Boston Bootcamp 2025 two months earlier, these companies began their journey to engage with the globally renowned Massachusetts (MA) life sciences ecosystem. The…
When it comes to unforeseen research disruptions, the most successful lab operations professionals hope for “if” but plan for “when.” Yet, a survey found that only 51% of businesses have continuity plans. Business continuity plans (BCPs) ensure labs can maintain critical functions, quickly resume normal operations, and prevent the loss of valuable research in the event of interruptions. This guide explores why and how to create a business continuity plan for your laboratory.
- Business continuity plans for labs- Benefits of a lab business continuity plan- Cheat sheet: 12 key elements for…
Riding the biotech wave: A durable bet for real estate?
Biotechnology – using biological science and living systems to develop new products – is often associated with pharmaceuticals. In reality, its impact extends far beyond human healthcare. Biotech innovations are quietly transforming agriculture, energy, materials, and even computing. From engineered crops and lab-grown meats to bio-based chemicals and renewable fuels, the use of biology as technology now permeates diverse industries. It is central to tackling some of the world's most critical challenges.
Structural tailwinds and…
Why the “biology-first, modality-agnostic” era is eclipsing yesterday’s size-based dogma
From bucketed modalities to a continuum mindset
For most of the modern drug-discovery era, chemists and biologists organised therapeutics along a rigid, size-driven taxonomy: small (< 500 Da), peptide, protein, gene, cell. That reductionist view served medicinal chemistry well when Lipinski’s rule-of-five was the dominant heuristic and gate-keeper of oral success, and when antibodies, oligonucleotides and viral vectors each lived in their own, distant technological silos.
Yet 2025’s pipeline tells a…
Anne Horgan, Partner at Cambridge Innovation Capital, talks about what makes her tick as an investor. She will chair the discussion on Nailing the Fundraise at BioBeat25. Co-organisers, Alisa Molotova, Start-up Mentor, and Miranda Weston-Smith, BioBeat founder chat with her about her role.
Q: How did you become an investor?
Anne: I would love to answer this question by saying that this was the result of a well thought-out 10 year career plan…the reality is somewhat less straightforward!
I am a scientist by training and after a PhD in organic chemistry at the…
by Tony Jones, CEO, One Nucleus
Trusting Your NeighboursContinuing down the thought process of the importance of nurturing your local ambassadors to enable your international success described in last month’s blog, I seek to explore the value of ensuring your company is not just recognised but also well understood within your local ecosystem, since nurturing success is a two-way process between all parties. It’s one thing for your neighbours to recognise you and know who you are; it is a step further for your neighbours to understand your goals and challenges unless you are open enough to…
by Monalisa Breazu, Learning & Development Administrator, One Nucleus
At a recent One Nucleus roundtable, a diverse group of professionals came together to talk candidly about this exact issue. From HR and hiring leads to scientists, educators, and entrepreneurs, we unpacked what’s working, what’s broken, and what needs to change.
Here’s what we learned and what we need to start doing differently.
From Science Backgrounds to Skills-First Hiring
A recurring theme was the debate around what constitutes a "science background“. Many attendees emphasised that having a PhD or even a STEM degree…